Date and time
Start: Thursday 21 November 2024, 09:00 AM
End: Friday 22 November 2024, 01:00 PM
Thursday 21 November
Start: Thursday 21 November 2024, 09:00 AM
End: Friday 22 November 2024, 01:00 PM
De Vere Tortworth Court, Tortworth, Wotton-under-Edge, GL12 8HH
We are currently operating a waiting list. To inquire about availability or to join the list, please contact us at [email protected]. If you have already booked a conference and would like to add accommodation for Wednesday, a few spots are still available. Please contact us at the email above to update your booking.
The annual CIPA Life Sciences Conference will take place on Thursday 21 and Friday 22 November at De Vere Tortworth Court Hotel in Wotton-under-Edge, Gloucestershire.
The CIPA Life Sciences Conference is the UK’s premier annual educational and networking event for patent and IP professionals active in the pharma, medical technology and biotechnology sectors. The Conference provides unrivalled expert insight into the latest developments in patents, regulatory and IP law in the global life science industry. Most importantly, the event provides a friendly environment for in-house and private practice professionals to network and share experiences.
The Conference will be preceded by an informal dinner on Wednesday evening in the 1853 Restaurant (Hotel’s Restaurant). No booking is necessary.
A formal dinner takes place on Thursday evening and will be preceded by a Pre-Dinner Speech by Sir Robin Jacob. The formal dinner is included in the Full Conference Package or can be purchased separately.
Please keep checking back for updates.
COST:
Members
Full Conference (including seminar on both days, Thursday accommodation and dinner) – £600 + VAT
Wednesday Accommodation – £137.50 + VAT (B&B, single occupancy)
Thursday Seminar – £300.00 + VAT
Thursday Dinner – £100.00 + VAT
Thursday Accommodation – £137.50 + VAT (B&B, single occupancy)
Friday Seminar – £120.00 + VAT
Non- Members
Full Conference (including seminar on both days, Thursday accommodation and dinner) – £870 + VAT
Wednesday Accommodation – £137.50 + VAT (B&B, single occupancy)
Thursday Seminar – £400.00 + VAT
Thursday Dinner – £120.00 + VAT
Thursday Accommodation – £137.50 + VAT (B&B, single occupancy)
Friday Seminar – £180.00 + VAT
All
Please note this is a provisional programme, subject to change.
Simon has a Chemistry (with Biochemistry) degree from Bristol University and qualified as a UK patent attorney in 1990. He became a European Patent Attorney in 1992 while with Kilburn & Strode and joined J A Kemp in 1994. He became a partner in J A Kemp’s biotechnology group in 2005 and moved to Schlich on the south coast in January 2022.
Simon handles patent (and trade mark) work in a wide variety of life science, chemical and pharma fields, including stem cells, human genes and genomics, drug delivery systems, contrast agents, GM crops, algae technology and CRISPR technology. He also handles mechanical work ranging from drones to electric vehicle charging. He works for a broad variety of clients ranging from individuals, SMEs and private clients up to UK universities and biotechnology start-ups. He also acts for EU and US genomics and academic institutions.
Simon has chaired CIPA’s Life Sciences Committee for 20 years, and now also Chairs the epi Biotech committee and the UNION biotech committees. He is a member of CIPA’s Council, Patents Committee and International Liaison Committee. He is a member of epi Council and the By-Laws committee and has been selected to be a member of SACEPO. He enjoys wine, gigs, playing the sax, running and cycling.
Dr Maria Nichol works as a consultant providing IP and business development strategic guidance to small biotechnology companies. Currently she acts as Chief Business Officer for Artax Biopharma, a US based biotech company working on a novel mechanism of action in the autoimmune disease space, and she is also Head of IP at Agomab, a European biotechnology company which is building a broad clinical pipeline of differentiated programs with disease modifying potential in organ failure and fibrotic diseases. Prior to this, Dr Nichol spent 17 years at Galapagos, where she initially built the IP team and was key in ensuring the strategic direction of the portfolio supported the commercial goals of the company, before moving into the Corporate Development team acting as a key member of the search and evaluation team and she was integral in many of their key transactions. Dr Nichol is a UK and European patent attorney, she graduated from Cambridge University in 1997 and holds a D.Phil from the University of Oxford.
Mathilda Davidson helps clients to exploit their intellectual property across a range of different markets and sectors. Mathilda is a legal director at international law firm Gowling WLG. She is a transactional IP and life sciences specialist and advises on the full spectrum of IP transactional issues in the life sciences sector and wider IP industries.
Mathilda advises companies and research institutions of all sizes on drug acquisition, collaboration and licensing deals. She has also spent time on secondment in the legal team of Cancer Research Technology (part of Cancer Research UK), where she advised on R&D partnerships with the international research community and commercialisation deals with industry, including an innovative international collaboration with public cancer registries around the world and the UN’s International Agency for Research on Cancer.
Mathilda has been recognized as a “Rising Star” by Managing Intellectual Property every year since 2018.
Dr Ula Cartwright-Finch is the Founder and Managing Director of Cortex Capital where she integrates psychology and neuroscience with law and business. Ula is an experienced international disputes lawyer and an expert in human behaviour. She holds a PhD in Cognitive Neuroscience from UCL and a MA in Psychology from the University of St Andrews. Ula also practiced international arbitration for over a decade in Europe and Asia. Ula is an Honorary Research Fellow at the University of Warwick and she lectures on Strategic Decision-Making for Lawyers at Queen Mary University of London. She is commissioned by international organisations including the International Bar Association to conduct original research on decision-making and diversity topics. She has won awards for her speaking and writing and is a well-known thinker in Legal Psychology.
Liz serves as VP Intellectual Property at Achilles Therapeutics, a Biotech company developing precision T cell therapies targeting clonal neoantigens. She has over 20 years’ experience as a patent attorney in both industry and private practice. Liz joined Achilles from D Young & Co, where she was a Senior Associate specialising in biotech patent work. Prior to that, Liz spent 9 years as Patent Counsel at GSK supporting the Vaccines business unit, with responsibility for a number of viral, bacterial and therapeutic vaccine projects and commercial products. Liz began her career in the Biotechnology and Life Sciences group at J A Kemp & Co where she qualified as a European and UK Chartered patent attorney. She has a MBiochem in Biochemistry and a MSc in Neuroscience from Oxford University. Liz is also a member of the EQE Examination Committee EC-I (A/B).
Dr Siqi Wang is the Head of Patents China for Spruson & Ferguson.
Siqi focuses on patent prosecution and advising on all aspects of China patent matters. Additional to general patent prosecution, Siqi’s professional practice also covers providing advice on Chinese patent matters including validity and infringement risk, Freedom to Operate (FTO), enforcement, patent strategy and local policy guidance.
Siqi has been working closely with overseas clients in various fields including world-class pharmaceutical corporations, leading chemistry companies, institutes and universities, as well as Associates from US, Europe and Australia. She has substantial experience in advising on macro-level China patent matters, with specialties in the fields of life sciences, pharmaceuticals and chemistry.
Siqi has been practicing as a Chinese Patent Attorney for over 14 years and has experience in representing clients for oral hearings for invalidation cases and legal hearings of administrative litigations in court. Prior to joining Spruson & Ferguson, Siqi worked with two prestigious Chinese IP agencies for eight years.
Siqi’s technical qualifications include a PhD degree in Cell Biology from the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences.
Eisan GO is a partner in life science groups of Aoyama & Partners. He has extensive experience on drafting/filing and prosecution of patent applications and patent term extensions particularly in the chemistry-based pharmaceutical fields. He specializes in pharmaceutical patents and assists clients of domestic and overseas multi-national companies and universities. He has also represented clients at invalidity proceedings before the JPO and assisted clients with patent litigation before IP courts in multiple countries as well as Japan. He is a member of the European and African working group of JPAA International Activities Center since 2015. He joined Aoyama & Partners in 2004 and was qualified as a Japanese Patent Attorney in 2009 and a Japanese Patent Infringement Litigator in 2011. He has a master’s degree in engineering from Osaka University, focusing on synthesis of organic small molecules useful for potential pharmaceuticals.
Claire Irvine, PhD, joined Beck Greener LLP in Of Counsel role in 2024 as one of the most experienced European and UK patent attorneys in the life sciences’ field. From her first days in the patent profession, Dr Irvine has been involved with many of the major innovations in the life sciences spanning immunotherapeutics, RNA therapeutics, synthetic biology, liquid biopsy and microbiome-related developments. In recent years, Dr Irvine has been much involved with innovations in the gene-editing field, especially applications of CRISPR-Cas technology, both therapeutic and diagnostic, and has advised many on the complexities of the CRISPR IP landscape including tech transfer bodies and corporate legal teams. Before joining Beck Greener, Dr Irvine was a patent partner in UK private practice for over 20 years.
Prior to her current role, Alice was a Senior Director in the department of Cell Therapy Innovation at Takeda Pharmaceuticals following the acquisition by Takeda of GammaDelta Therapeutics at the beginning of this year, where Alice had held the roles of VP Research and, before that, VP Gene Engineering.
At GammaDelta Alice built and lead the research team and was responsible for developing multiple cell therapy programs from discovery through to completion of pre-clinical development. Alice joined GammaDelta from PsiOxus Therapeutics where she was the Director of Biology.
She holds a degree and PhD in Biochemistry from the University of Bristol and carried out her post-doctoral research in Immunology at Imperial College London.
Sir Robin Jacob is the Sir Hugh Laddie Chair of Intellectual Property Law at UCL and acts as an arbitrator, mediator, expert determiner and expert witness both in IP and commercial cases. He is a member of the following arbitral bodies: LCIA, the ICC, SIAC, KLRC and HKIAC.
Having read Natural Sciences at Trinity College Cambridge, Sir Robin then simultaneously read for the Bar and took an LLB from the LSE. He was called to the Bar by Gray’s Inn in 1965.
He practiced at the IP Bar from 1967, was appointed Queen’s Counsel in 1981 and had a busy international practice (Hong Kong, Singapore, Europe, USA, Australia) until he was appointed to the Bench in 1993. From 1997 to 2001 he was Supervising Chancery Judge for Birmingham, Bristol and Cardiff. Sir Robin was appointed a Lord Justice of Appeal in October 2003.
In the Court of Appeal, he regularly sat on both IP and commercial cases. He formally retired from the Court of Appeal in May 2011 to take up his current appointment, continuing to sit from time to time in the Court of Appeal until April 2016.
He is an Hon. Fellow of the LSE, an Hon. Fellow of St Peter’s College, Oxford, an Hon. LID of the University of Wolverhampton, Hon. President of the UK branch of the Licensing Executive Society, Hon. President of the Association of Law Teachers and a member of the Advisory Board of the European Law Centre of King’s College London. He was Treasurer of Gays Inn in 2007 and a Governor of the LSE from 1996 to 2016.
Sir Robin is President of the Intellectual Property Judges’ Association (the association of European IP, particularly patent, judges). He was Chairman of the Advisory Panel on the Selection and Training of Judges for the Unified Patent Court until the UK withdrew from the project.
Sir Robin Jacob is the Sir Hugh Laddie Chair of Intellectual Property Law at UCL and acts as an arbitrator, mediator, expert determiner and expert witness both in IP and commercial cases. He is a member of the following arbitral bodies: LCIA, the ICC, SIAC, KLRC and HKIAC.
Having read Natural Sciences at Trinity College Cambridge, Sir Robin then simultaneously read for the Bar and took an LLB from the LSE. He was called to the Bar by Gray’s Inn in 1965.
He practiced at the IP Bar from 1967, was appointed Queen’s Counsel in 1981 and had a busy international practice (Hong Kong, Singapore, Europe, USA, Australia) until he was appointed to the Bench in 1993. From 1997 to 2001 he was Supervising Chancery Judge for Birmingham, Bristol and Cardiff. Sir Robin was appointed a Lord Justice of Appeal in October 2003.
In the Court of Appeal, he regularly sat on both IP and commercial cases. He formally retired from the Court of Appeal in May 2011 to take up his current appointment, continuing to sit from time to time in the Court of Appeal until April 2016.
He is an Hon. Fellow of the LSE, an Hon. Fellow of St Peter’s College, Oxford, an Hon. LID of the University of Wolverhampton, Hon. President of the UK branch of the Licensing Executive Society, Hon. President of the Association of Law Teachers and a member of the Advisory Board of the European Law Centre of King’s College London. He was Treasurer of Gays Inn in 2007 and a Governor of the LSE from 1996 to 2016.
Sir Robin is President of the Intellectual Property Judges’ Association (the association of European IP, particularly patent, judges). He was Chairman of the Advisory Panel on the Selection and Training of Judges for the Unified Patent Court until the UK withdrew from the project.
Jim head up the life sciences team at Lawrie IP.
With over 25 years’ experience, Jim’s technical fields include diagnostics and therapeutics, molecular and cellular biology, antigens and antibody-based technologies, microbiology, medical devices, digital healthtech, synthetic biology, personalised medicine, regenerative medicine, agritech, plants and biopesticides.
Motivated by helping his clients’ businesses thrive, Jim protects their products and technologies by drafting, filing and prosecuting patent applications, managing patent portfolios, and handling contentious proceedings such as oppositions and revocations. He also undertakes due diligence on commercial transactions and performs freedom to operate work.
His expertise allows his clients to get on with building their own successful businesses while he looks after their IP.
Oliver Jan Jüngst has been with Bird & Bird LLP since the opening of the first German office in Düsseldorf in 2002. Oliver has 25 years’ history of litigating patents on both sides of the ”v.”
His special area of expertise is the organisation and implementation of international patent infringement litigation. Oliver handles patent cases before all German Courts, the European Patent Office as well as the Unified Patent Court. He has run several of the largest patent cases in Germany and appeared in the first-ever substantive hearing before the UPC for NanoString Technologies Inc., in the Munich Local Division and the Court of Appeal in Luxembourg, respectively.
You will find Oliver Jan Jüngst listed in numerous reputable legal directories such as The Legal500, Chambers, JUVE Patents, Best Lawyers, Who’s Who Legal, Managing Intellectual Property and IAM Patent.
Dr Shohta Ueno is a Senior Director Assistant General Counsel, Dispute Resolution at Regeneron Pharmaceuticals Inc., a leading biopharmaceutical company where he advises the company on a broad range of complex, multi-jurisdictional disputes. While Shohta deals with all matters relating to disputes, he focuses mostly on non-US IP matters and helps the company navigate through increasingly complex IP landscape. Shohta joined Regeneron in 2018 from a leading IP litigation practice based in the UK. Shohta is also a trained scientist – he obtained a PhD in Virology as well as an undergraduate degree in Natural Sciences from the University of Cambridge.
Shohta currently serves on the Pharma Committee of the AIPPI and on the Life Sciences Committee on the Chartered Institute of Patent Attorneys and is a member of the council of the IP Federation. Shohta was recognised as a notable UK practitioner by IP Stars 2024.
David was a UK solicitor for over 35 years before he left GSK at the end of 2018.
After 15 years doing contentious and non-contentious patent work at Clifford Chance, he joined GSK about 20 years ago.
David was Vice-President Intellectual Property Policy at GSK where he worked on numerous complex policy issues and initiatives. He was GSK’s IP representative in major UK, US and international pharmaceutical industry and cross-industry associations and chaired the IP committee of EFPIA, the European pharmaceutical industry association for over 10 years.
He was involved in developing GSK’s strategies for IP and access to medicines and was a member of the Expert Advisory Group to the UN High Level Panel on Access to Medicines. He led the IP aspects of industry involvement in the European Commission’s sector inquiry into the pharmaceutical (2008-2009). He was deeply involved in the creation of two ground-breaking collaborations between industry and the WIPO; WIPO Research (created in 2011 which makes IP available for use in neglected disease research) and Pat-INFORMED (created in 2018 which makes patent information available to procurement agencies). He was appointed to a Commission expert group which drafted the rules of procedure for the UPC and was largely responsible for inclusion of the opt out option in that Court.
He has been responsible for lobbying UK government and European institutions on a wide range of issues varying from the UPC, the SPC export waiver, the Convention on Biological Diversity and, of course, Brexit.
He has twice been named among Managing IP’s top 50 influential people in IP.
Since leaving GSK, he has worked as a consultant and adviser to various trade associations.
Jim head up the life sciences team at Lawrie IP.
With over 25 years’ experience, Jim’s technical fields include diagnostics and therapeutics, molecular and cellular biology, antigens and antibody-based technologies, microbiology, medical devices, digital healthtech, synthetic biology, personalised medicine, regenerative medicine, agritech, plants and biopesticides.
Motivated by helping his clients’ businesses thrive, Jim protects their products and technologies by drafting, filing and prosecuting patent applications, managing patent portfolios, and handling contentious proceedings such as oppositions and revocations. He also undertakes due diligence on commercial transactions and performs freedom to operate work.
His expertise allows his clients to get on with building their own successful businesses while he looks after their IP.
Andrea L.C. Reid, co-chair of Dechert’s intellectual property practice, co-head of Dechert’s patent counseling and prosecution team, co-lead of Dechert’s global life sciences group and member of the firm’s policy committee, counsels established and start-up clients in all sectors of the biotech and pharmaceutical industries on developing IP strategies, patent portfolio management and transactions at all phases of the business cycle. Ms. Reid’s ability to develop successful IP strategies for U.S. and European clients has resulted in more than US$30 billion in acquisition and investor/partner funding. With more than 30 years of experience working in the pharmaceutical industry, she has extensive experience in all areas of drug discovery through drug development. She draws on this experience when prosecuting patent applications and preparing patentability, validity and infringement opinions involving active pharmaceutical ingredients, manufacturing syntheses and formulations. She regularly represents clients on specialty issues relating to organic chemistry, small molecule pharmaceuticals and polymorph IP.
Joel is a patent associate with Potter Clarkson in London and specialises in the life sciences, with experience in the drafting and prosecution of patent applications and prosecution of supplementary protection certificates.
Joel brings a strong background in research to the team, particularly in the areas of stem cell technologies and neurodegenerative diseases such as Parkinson’s.
He has assisted the CIPA Life Science Committee on matters relating to sequence listings and supplementary protection certificates, including co-authoring articles in the CIPA Journal on the changes to SPC legislation in the UK resulting from Brexit.
RWS is the world’s leading provider of technology-enabled language, content management, and intellectual property services. With over 60 years of experience in the IP arena, RWS’s expertise in patent translations, foreign filing and IP research services is unrivalled.
Clients trust RWS to deliver high-quality translations in a format ready for filing, in compliance with national filing formalities, and maintaining the same protective scope as the original.
RWS also helps clients simplify and streamline their internal processes, by providing flexible, cost-effective foreign filing services that dramatically reduce the administrative burden associated with EP validations, PCT national phase entries and direct filings.
When it comes to research, RWS offers the most robust intellectual property (IP) research services and tools available. AOP Connect, RWS’s market leading patent research platform, enables clients to store, manage, search and organise study data for future use. With search solutions to meet a vast range of needs, from analyst studies to crowd-based searches, RWS .
RWS clients include many of the world’s largest filers including 19 of the top 20 applicants at the World Intellectual Property Organization and 16 of the top 20 applicants at the European Patent Office.
Founded in 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L).
PatWorld Research Services
Established by brothers, Dean Parry MSC (former UKIPO Examiner and scientific researcher) and Tim Parry MBA (an expert in Business and Marketing across a number of industries), they have built an impressive track record, since 2005 the team at PatWorld been consistently delivering exceptional research and customer service to IP Professionals, Tech companies and Universities Worldwide.
Contact us with your search request today:
PatWorld Database
Your Ultimate AI-Powered Patent Research Tool. PatWorld is the cutting-edge patent research platform revolutionizing the way professionals access patent information. Boasting seamless integration of Ai, analytics, project management tools, and collaborative features, PatWorld is the go-to choice for professionals worldwide, with subscription options to fit every budget.
Contact us for a free (no obligation Demo and Trial):
PatWorld Training Course
We have been training professional researchers for over 20 years. Now you can gain CPD points and learn searching with our new online “Introduction to Patent Searching” course designed for busy people wanting to improve their understanding and skills. The 7 hour online course offers the flexibility of starting whenever you want and gives a full month to complete the course.
Patent documents protect the work of individuals, articulate clarity and dispel ambiguity – all factors that must remain as part of a translation. Our specialists, who include former patent agents, cover the full spectrum of patent documents and processes, including PCT National Filings, Unitary Patent applications, EP Validations and Intellectual Property Litigation. They have detailed industry insight into the multitude of subjects and sectors that patent law can cover, from aerospace to healthcare. We never forget that poor translation can weaken protection and affect important deadlines.
At ABC Translations we provide meticulous accuracy, using the correct patent terminology, for a wide range of patent customers, from sole trader patent attorneys to Formalities departments of large firms and IP divisions of large multi-nationals.
Start: Tuesday 25 February 2025, 05:30 PM
End: Tuesday 25 February 2025, 06:30 PM
Start: Thursday 20 March 2025, 12:30 PM
End: Thursday 20 March 2025, 07:00 PM
Start: Thursday 15 May 2025, 12:30 PM
End: Thursday 15 May 2025, 07:00 PM
Start: Thursday 13 February 2025, 12:30 PM
End: Thursday 13 February 2025, 07:30 PM
Start: Tuesday 25 March 2025, 08:00 AM
End: Tuesday 25 March 2025, 05:00 PM
Start: Wednesday 12 March 2025, 12:30 PM
End: Wednesday 12 March 2025, 07:30 PM
Start: Wednesday 15 January 2025, 12:30 PM
End: Wednesday 15 January 2025, 01:30 PM
Start: Thursday 27 March 2025, 12:30 PM
End: Thursday 27 March 2025, 07:00 PM
Start: Thursday 8 May 2025, 12:30 PM
End: Thursday 8 May 2025, 07:00 PM
Start: Wednesday 26 February 2025, 09:30 AM
End: Wednesday 26 February 2025, 06:30 PM
Sign in to your account to register for the event
If you are not yet registered or a member of CIPA, please register here